Femasys Q2 2025 sales up 85% to $409K, net loss $4.6M, cash runway into early Q4

FEMASYS INC

2025-Q2 EPS reported -$0.39 vs consensus -$0.18 ▼ miss (-112.4%)

Sales $409,268 (+84.8% YoY); net loss $4.59M ($0.16/sh) vs $4.68M ($0.21/sh) prior year.
Cash $3.2M, accumulated deficit $137.7M; expects current cash to fund ops into early Q4 2025.
EU MDR approval for FemBloc non-surgical birth control; first $400K order from Spain.
Australia/New Zealand approvals for FemaSeed and FemVue; partnered with Carolinas Fertility Institute.
Closed $4.5M public offering and private placement for working capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.